1. Moderna. Moderna’s therapeutics: relaxin (mRNA-0184). https://investors.modernatx.com/static-files/61a4dae1-56ca-403f-b573-0602faf774eb
2. Moderna. Moderna announces first participant dosed in phase 1/2 study of its quadrivalent seasonal flu mRNA vaccine. 7 Jul 2021. https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-first-participant-dosed-phase-12-study-its
3. A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection
4. BioNTech. BioNTech provides update on plans to develop sustainable solutions to address infectious diseases on the African continent. https://investors.biontech.de/news-releases/news-release-details/biontech-provides-update-plans-develop-sustainable-solutions
5. The tangled history of mRNA vaccines